Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 6/20 | 0.33 |
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11972585 | 0.82 | DPP4 (0.42) | DPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL19882810 | 0.81 | PIK3CD (0.39) | DPP4FPR2PIK3CDCNR1CNR2 | |
| SCHEMBL29645831 | 0.81 | PIK3CD (0.39) | DPP4FPR2PIK3CDCNR1CNR2 | |
| SCHEMBL2735577 | 0.78 | DPP4 (0.46) | DPP4ALDH1A1MAPTPTGS1ARG1 | |
| SCHEMBL8034816 | 0.78 | DPP4 (0.46) | DPP4ALDH1A1MAPTPTGS1ARG1 | |
| SCHEMBL10311712 | 0.76 | PIK3CD (0.42) | DPP4FPR2PIK3CDCNR1CNR2 | |
| SCHEMBL4126708 | 0.75 | FPR2 (0.35) | FPR2PIK3CDCNR1CNR2TRPA1 | |
| SCHEMBL1337609 | 0.75 | USP2 (0.50) | DPP4CNR1ALDH1A1MAPTPTGS1 | |
| SCHEMBL12898741 | 0.75 | ALDH1A1 (0.50) | DPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL1337607 | 0.75 | USP2 (0.50) | DPP4CNR1ALDH1A1MAPTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | DPP4 4359/4885FPR2 229/4885PIK3CD 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.